Cardio-Oncology
Definition
Cardio-oncology is an emerging clinical discipline integrating cardiovascular (CV) medicine, oncology, and haematology to allow patients with cancer to receive the best possible cancer treatments safely while minimizing cancer therapy-related cardiovascular toxicity (CTR-CVT) across the entire continuum of cancer care — from pre-treatment baseline assessment, through active treatment surveillance, to long-term cancer survivorship.
Key Concepts
Guiding Principles
- Integration is the cardinal principle: cardio-oncology providers must have knowledge of cardiology, oncology, and haematology. Communication between disciplines is critical. (sources/Cardio-Oncology-ESC-2022, rating: very high)
- The goal is not to prevent cancer therapy, but to enable it safely — minimizing unnecessary treatment interruptions and optimizing CV health in parallel. (sources/Cardio-Oncology-ESC-2022)
- CTR-CVT risk is a dynamic variable that changes throughout the pathway of care: it depends on baseline patient risk factors, type/dose/duration of anticancer therapy, emergence of CV complications during treatment, and cumulative treatment history in survivors. (sources/Cardio-Oncology-ESC-2022)
Cardio-Oncology Care Pathways
- Before cancer treatment: Baseline CV toxicity risk assessment (Class I for all patients receiving potentially cardiotoxic agents). (sources/Cardio-Oncology-ESC-2022)
- During treatment: Cancer treatment surveillance according to drug type and baseline risk; early management of CTR-CVT.
- First year after treatment: End-of-treatment CV risk assessment (Class I); plan long-term follow-up.
- Long-term (>1 year post-treatment): Annual CV risk assessment and CVRF management for high-risk survivors. (sources/Cardio-Oncology-ESC-2022)
Risk Stratification — HFA-ICOS Tool
- Patients are stratified as Low / Moderate / High / Very High risk using the HFA-ICOS tool (Class IIa/C), applied separately for each cancer treatment category (anthracyclines, HER2-targeted, VEGFi, BCR-ABL TKIs, MM therapies, RAF/MEK inhibitors). (sources/Cardio-Oncology-ESC-2022)
- See concepts/HFA-ICOS-Risk-Stratification for detailed scoring.
Multidisciplinary Team (MDT)
- MDT discussion is required when patients with cancer have complex CVD that may impact cancer treatment decisions, or when CTR-CVT develops and requires balancing risk/benefit of treatment continuation. (sources/Cardio-Oncology-ESC-2022)
- Cardio-oncology referral is recommended (vs. general cardiology) when available.
Cancer Survivors
- Long-term CV complications of prior cardiotoxic cancer therapy include: cardiomyopathy, coronary artery disease, valvular disease, pericardial disease, arrhythmias.
- Childhood cancer survivors treated with anthracyclines ≥250 mg/m² doxorubicin-equivalent or mediastinal RT are at highest long-term risk and require protocol-based echocardiographic surveillance. (sources/Cardio-Oncology-ESC-2022)
Multimodality Cardiovascular Imaging Framework
- Major paradigm shift: The AHA 2023 Scientific Statement establishes that the historical focus on LVEF alone is insufficient for contemporary cancer therapies. Multimodal imaging spanning echocardiography, CMR, CCT, and nuclear imaging is now the standard. (sources/imaging-cardio-oncology-aha-2024, rating: high)
- Echocardiography remains first-line; GLS (absolute <16% or >15% relative decline) is a key marker for subclinical cardiotoxicity even with preserved LVEF.
- CMR is second-line — principally for suspected ICI myocarditis, complex differentials (toxic vs. ischaemic vs. inflammatory), and scar/fibrosis quantification. T1/T2 mapping predicts MACE in ICI-treated patients.
- CCT adds value for ASCVD/CAC risk stratification in cancer survivors and as noninvasive ACS workup for fluoropyrimidine/ICI patients at high bleeding risk.
- Nuclear imaging: MUGA is third-line only; 99mTc-PYP SPECT is the preferred modality for suspected cardiac ATTR amyloidosis in cancer patients.
- Imaging intensity is modulated by therapy type and clinical presentation — see detailed tables in concepts/Cancer-Therapy-Related-CV-Toxicity.
- Disparities: Black patients and women are underrepresented in cardio-oncology imaging access and have disproportionately higher cardiotoxicity burden; dedicated cardio-oncology referral with serial imaging is protective.
- (sources/imaging-cardio-oncology-aha-2024)
Hormonal Therapy Cardiovascular Risk
- Hormonal therapies (endocrine therapy for breast cancer; ADT for prostate cancer) are an underappreciated source of CVD morbidity — they improve cancer survival but increase CV events. (sources/Hormonal-Rx-AHA-2021, rating: high)
- Aromatase inhibitors carry higher arterial CVD risk than tamoxifen (pooled RR 1.19); tamoxifen markedly increases VTE but is itself cardioprotective for arterial events vs. placebo.
- CDK4/6 inhibitors combined with endocrine therapy add QT prolongation (ribociclib) and hypertension (palbociclib); ribociclib + tamoxifen combination (>5% QTc >480 ms) should be avoided.
- GnRH antagonists (relugolix, degarelix) are preferred over GnRH agonists in men with pre-existing symptomatic CAD — HERO trial: major CV events 2.9% vs. 6.2% (HR 0.46).
- The ABCDE algorithm (Awareness/Aspirin, Blood pressure, Cholesterol/Cigarettes, Diet/Diabetes, Exercise/ECG/Echo) structures cardioprotection during hormonal therapy.
- See concepts/Hormonal-Therapy-CV-Risk for comprehensive drug-by-drug detail.
- (sources/Hormonal-Rx-AHA-2021)
Arrhythmias and Autonomic Dysfunction
- Arrhythmias are an increasingly identified complication of cancer therapy with unique management challenges. AF is the most common (2–16% during active treatment), but QT prolongation, ventricular arrhythmias, and bradyarrhythmias also occur across all major drug classes. See concepts/Cancer-Associated-Arrhythmia for the full drug-by-drug framework. (sources/arrhythmia-cardio-oncology-aha-2021, rating: very high)
- Key drug–arrhythmia associations: Ibrutinib (BTK inhibitor) has the highest AF incidence (RR 4.69); arsenic trioxide causes QT prolongation in 26–93%; ICI-associated high-degree AV block may be the first sign of myocarditis. (sources/arrhythmia-cardio-oncology-aha-2021)
- Anticoagulation in cancer-AF is complex: standard CHA₂DS₂-VASc underestimates stroke risk; HAS-BLED does not capture thrombocytopenia or brain metastases; apixaban was superior to warfarin in ARISTOTLE cancer subgroup (n=1,236). (sources/arrhythmia-cardio-oncology-aha-2021)
- Autonomic dysfunction (decreased HRV, orthostatic hypotension, IST/POTS) is prevalent in cancer survivors and is associated with increased fatigue, reduced exercise capacity, and mortality. Structured aerobic exercise reverses AD; ivabradine is a candidate for IST. See concepts/Autonomic-Dysfunction-in-Cancer. (sources/arrhythmia-cardio-oncology-aha-2021)
AI and Precision Medicine in Cardio-Oncology
- AI can integrate imaging, multi-omics, EHR data, and ECG signals to individualise cardiotoxicity risk prediction far beyond single-modality approaches. (sources/ai-cardiooncology-aha-2025, rating: high)
- Key AI-enabled applications include automated LVEF measurement (RCT-validated), ECG-based LV dysfunction detection in anthracycline/trastuzumab patients, and NLP-driven EHR data extraction for high-risk patient identification. (sources/ai-cardiooncology-aha-2025)
- Multi-omics biomarkers (genomics — TTNtv, RARG; transcriptomics — ICI myocarditis T-cell subsets; proteomics — hemopexin; metabolomics — TCA cycle metabolites) are under active investigation but remain pre-clinical. (sources/ai-cardiooncology-aha-2025)
- A national cardio-oncology registry is needed to enable representative AI model training — must include community hospitals to avoid selection bias. (sources/ai-cardiooncology-aha-2025)
- See concepts/AI-in-Cardio-Oncology for detailed coverage of AI applications.
Shared Cancer-CVD Risk Factors and CHIP
Cancer and CVD share common modifiable and genetic risk factors — a paradigm with major public health implications for the >16 million cancer survivors. (sources/cardio-oncology-vascular-metabolic-aha-2019, rating: very high)
- Lifestyle/metabolic risk factors: ARIC study — adherence to all 7 AHA 2020 cardiovascular health metrics is inversely associated with both CVD AND cancer (breast, colorectal, lung most strongly). Tobacco is an established shared risk. (sources/cardio-oncology-vascular-metabolic-aha-2019)
- Cholesterol and breast cancer: Dietary cholesterol top quartile → 48% ↑ breast cancer risk; 27-hydroxycholesterol (cholesterol metabolite) acts as direct estrogen receptor agonist in breast cancer cells → shared biological mechanism. Statins therefore may have dual benefit. (sources/cardio-oncology-vascular-metabolic-aha-2019)
- Inflammation (IL-1β): CANTOS trial — canakinumab reduced both cardiac events and lung cancer incidence/mortality, implicating a shared inflammatory pathway. (sources/cardio-oncology-vascular-metabolic-aha-2019)
- Clonal Hematopoiesis (CH/CHIP): Expanded somatic blood cell clone driven by DNMT3A, TET2, ASXL1, JAK2 V617F (and DDR pathway variants in therapy-related CH) without haematological abnormality; associated with both hematologic malignancy risk AND CVD. A 2026 AHA Scientific Statement provides a comprehensive update: DNMT3A/TET2/ASXL1 CH → 1.7–2× higher ASCVD risk; 25% higher HF risk (meta-analysis n=56,597); TET2 2.4× enriched in HFpEF; JAK2 V617F → arterial and venous thrombosis. Therapy-related CH (t-CH) — selected by cytotoxic chemotherapy and radiation — amplifies late cardiotoxicity: TP53-CH worsens anthracycline cardiomyopathy; PPM1D-CH drives myocardial fibrosis via NLRP3/IL-1β. Gene-specific mechanisms: TET2 LOF → NLRP3 inflammasome/IL-1β (CANTOS post-hoc shows canakinumab benefit specifically in TET2-CH carriers); DNMT3A LOF → impaired efferocytosis + HB-EGF-driven cardiac fibrosis. CHIP clinics at tertiary centres provide multidisciplinary haematologic + CV risk surveillance. Current CVD risk models (PREVENT, SCORE2) do not incorporate CH — guideline-concordant prevention is recommended until CH-specific CVD therapies are proven. See concepts/Clonal-Hematopoiesis. (sources/cardio-oncology-vascular-metabolic-aha-2019, sources/ch-aha-2026, rating: very high)
Cancer-Associated VTE
VTE is the most common cardiovascular complication of malignancy — more common than CTRCD — and is both a management challenge and a prognostic marker. See concepts/Cancer-Associated-VTE for full detail. (sources/cardio-oncology-vascular-metabolic-aha-2019, rating: very high)
- Cancer increases VTE risk 7–8×; cancer-VTE increases mortality 5–6× vs. non-cancer VTE. (sources/cardio-oncology-vascular-metabolic-aha-2019)
- Ottawa Score predicts recurrence (score ≤0 = <4.5% risk; ≥1 = ~19% risk). (sources/cardio-oncology-vascular-metabolic-aha-2019)
- LMWH preferred over VKA (dalteparin, enoxaparin superiority demonstrated); DOACs are emerging as non-inferior or superior alternatives. (sources/cardio-oncology-vascular-metabolic-aha-2019)
Vascular Perspectives — Cancer as a Vascular Disease
The elevated cardiovascular risk in cancer patients extends well beyond cardiomyopathy and arrhythmias into vascular disease: (sources/cardio-oncology-vascular-metabolic-aha-2019, rating: very high)
- Radiation vasculopathy: Premature CAD (Hodgkin lymphoma, breast cancer survivors); carotid disease after neck RT; autonomic dysfunction (4× higher resting HR; 5× higher abnormal HRR; 4-fold all-cause mortality increase in Hodgkin survivors post-mediastinal RT). Surveillance: stress testing 5–10 years post-mediastinal RT; carotid ultrasound post-neck RT. (sources/cardio-oncology-vascular-metabolic-aha-2019)
- VEGF inhibitor hypertension: ≥25% incidence (class effect; >50% with newer agents); mechanism is ↓ NO + ↑ endothelin-1 + capillary rarefaction + renal sodium retention; avoid diltiazem/verapamil; preferred agents ACE-I + amlodipine. See concepts/Cancer-Therapy-Related-CV-Toxicity. (sources/cardio-oncology-vascular-metabolic-aha-2019)
- Fluoropyrimidine coronary vasospasm: Up to 5.4% with continuous infusion; predominantly within 72h of first cycle; rechallenge only with CCB + nitrate prophylaxis in monitored setting. (sources/cardio-oncology-vascular-metabolic-aha-2019)
- ABL inhibitor vascular divergence: Imatinib has vascular-protective profile; nilotinib causes atherosclerosis/PAD; ponatinib causes arterial/venous occlusions in ≥27%; dasatinib causes PAH — all off-target effects dissociable from ABL1 inhibition. (sources/cardio-oncology-vascular-metabolic-aha-2019)
Contradictions / Open Questions
- Dedicated cardio-oncology services are scarce — most patients are managed in general cardiology clinics; there is limited RCT evidence to define optimal surveillance strategies.
- HFA-ICOS risk assessment tools require prospective validation; most evidence supporting them is retrospective.
- Optimal duration of cardioprotective medications (e.g. ACE-I/beta-blockers started during cancer treatment) after therapy completion is undefined. (sources/Cardio-Oncology-ESC-2022)
- No AI risk prediction tools have been prospectively validated in clinical trials; cardiotoxicity definitions are inconsistent across studies, complicating AI model development. (sources/ai-cardiooncology-aha-2025)
- Biomarker-guided cardioprotection (troponin-guided enalapril; hsTnI-guided candesartan/carvedilol) did not outperform universal cardioprotection in RCTs — AI-enhanced biomarker integration awaits clinical testing. (sources/ai-cardiooncology-aha-2025)
Connections
- Related to concepts/Cancer-Therapy-Related-CV-Toxicity
- Related to concepts/AI-in-Cardio-Oncology
- Related to concepts/HFA-ICOS-Risk-Stratification
- Related to concepts/Cardiac-Amyloidosis-Imaging
- Related to entities/Heart-Failure
- Related to entities/Atrial-Fibrillation
- Related to sources/Cardio-Oncology-ESC-2022
- Related to sources/ai-cardiooncology-aha-2025
- Related to sources/imaging-cardio-oncology-aha-2024
- Related to concepts/Cancer-Associated-Arrhythmia
- Related to concepts/Autonomic-Dysfunction-in-Cancer
- Related to sources/arrhythmia-cardio-oncology-aha-2021
- Related to concepts/Hormonal-Therapy-CV-Risk
- Related to sources/Hormonal-Rx-AHA-2021
- Related to concepts/Cancer-Associated-VTE
- Related to concepts/Clonal-Hematopoiesis — CH as emerging cancer-CVD shared risk factor; CHIP clinics; t-CH amplifies late cardiotoxicity from chemotherapy/radiation
- Related to sources/cardio-oncology-vascular-metabolic-aha-2019
- Related to sources/ch-aha-2026